Difluprednate
Active ingredient · 2 therapeutic classes
Sold as DUREZOL
- Drug class
- Corticosteroids, Potent (Group Iii)
- Availability
- Prescription only
- Routes
- Ophthalmic
- Markets covered
- 2
- Products on record
- 5
- FDA reports (12 mo)
- 147
Overview
Difluprednate is an active pharmaceutical ingredient in the Corticosteroids, Potent (Group Iii) group (D07AC). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 4 | September 24, 2025 |
| CA Canada | Health Canada | 1 | March 22, 2025 |
USUnited States· FDA
4 products
Uses
05%, a topical corticosteroid, is indicated for the treatment of inflammation and pain associated with ocular surgery. 2 Endogenous Anterior Uveitis Difluprednate ophthalmic emulsion is also indicated for the treatment of endogenous anterior uveitis.
05%, a topical corticosteroid, is indicated for the treatment of inflammation and pain associated with ocular surgery. 2 Endogenous Anterior Uveitis Difluprednate ophthalmic emulsion is also indicated for the treatment of endogenous anterior uveitis.
How to take
CACanada· Health Canada
1 product
Uses
AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS .................................................................................................. 4 WARNINGS AND PRECAUTIONS .................................................................................
4 ADVERSE REACTIONS ................................................................................................... 8 DRUG INTERACTIONS .................................................................................................
13 DOSAGE AND ADMINISTRATION ............................................................................. 13 OVERDOSAGE................................................................................................................
14 ACTION AND CLINICAL PHARMACOLOGY ........................................................... 14 STORAGE AND STABILITY ......................................................................................... 15 SPECIAL HANDLING INSTRUCTIONS ......................................................................
Sources & citations
- [1]FDA DailyMed · 054ca798-454a-41… · revised February 8, 2025 [PDF]
- [2]Health Canada (DPD) · 02415534 · revised March 22, 2025
- [3]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.